Abstract
Rationale有关特发性肺纤维化(IPF)的抗灰度疗法的观察数据缺乏缺乏观察数据。
目的We aimed to assess the course of disease of IPF patients with and without antifibrotic therapy under real-life conditions.
方法我们分析了来自德国20个ILD专家中心的连续注册的IPF患者的非介入性,前瞻性队列研究的数据。通过自动合理性检查,现场监控和源数据验证确保数据质量。施用倾向分数考虑有没有抗纤维化治疗的患者之间的基线特征的已知差异。
ResultsAmong the 588 patients suitable for analysis, the mean age was 69.8±9.1 years, and 81.0% were males. The mean duration of disease since diagnosis was 1.8±3.4 years. The mean % predicted value at baseline for forced vital capacity (FVC) and diffusion capacity (DLCO) were 68.6±18.8 and 37.8±18.5, respectively. During a mean follow-up of 1.2±0.7 years, 194 (33.0%) patients died. The one-year and two-year survival rates were 87%versus46%和62%versus21%, respectively, for patients withversuswithout antifibrotic therapy. The risk of death was 37% lower in patients with antifibrotic therapy (HR=0.63, 95%CI: 0.45; 0.87; p=0.005). The results were robust (and remained statistically significant) on multivariable analysis. Overall decline of FVC and DLco was slow and did not differ significantly between patients with or without antifibrotic therapy.
Conclusions年代urvival was significantly higher in IPF patients with antifibrotic therapy, but the course of lung function parameters was similar in patients with and without antifibrotic therapy. This suggests that in clinical practice premature mortality of IPF patients eventually occurs despite stable measurements for FVC and DLco.
脚注
此手稿最近被接受了出版物European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theERJ线上。请打开或下载PDF以查看本文。
Conflict of interest: Dr. Behr reports grants and personal fees from Boehriger Ingelheim, personal fees from Actelion, personal fees from Roche, personal fees from Galapagos, personal fees from Promedior, personal fees from BMS, personal fees from MSD, during the conduct of the study.
Conflict of interest: Dr. Prasse reports grants and personal fees from Roche/InterMune, grants and personal fees from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: Dr. Wirtz reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: Dr. Koschel has nothing to disclose.
利益冲突:Pittrow博士报告了拜耳的个人费用,拜耳的个人费用,Boehringer Ingelheim的个人费用,来自Sanofi的个人费用,Biogen的个人费用,盾牌的个人费用,盾牌的个人费用,来自MSD的个人费用,在提交的工作之外。
Conflict of interest: Dr. Held has nothing to disclose.
Conflict of interest: Dr. Klotsche has nothing to disclose.
利益冲突:Andreas博士报告了Boehringer Ingelheim的赠款和个人费用,从罗氏的个人费用,在提交的工作之外。
Conflict of interest: Dr. Claussen reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: Dr. Grohé has nothing to disclose.
Conflict of interest: Dr. Wilkens reports personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Actelion, personal fees from Biotest, personal fees from GSK, personal fees from Pfizer, personal fees from Bayer, outside the submitted work.
Conflict of interest: Dr. Hagmeier has nothing to disclose.
Conflict of interest: Dr. Skowasch reports personal fees from Boehringer Ingelheim, personal fees from Roche, outside the submitted work.
兴趣冲突:Meyer博士从诺特利姆的Boehringer Ingelheim报告个人费用,从诺特里斯的个人费用之外提交的工作。
Conflict of interest: Dr. Kirschner has nothing to disclose.
Conflict of interest: Dr. Gläser reports grants and personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Actelion, grants and personal fees from Novartis, personal fees from Berlin Chemie, personal fees from Astra, outside the submitted work.
利益冲突:Kahn博士没有披露。
利益冲突:博士Welte赠款和报告personal fees from Boehringer Ingelheim, grants from Roche, outside the submitted work.
兴趣冲突:Neurohr博士报告了Boehringer Ingelheim的个人费用,罗氏的个人费用,在提交的工作之外。
Conflict of interest: Dr. Schwaiblmair has nothing to disclose.
利益冲突:Bahmer博士报告德国肺部研究(DZL)的授权,罗氏的个人费用,阿拉西卡纳的个人费用,柴迪的个人费用,GSK的个人费用,诺特克斯的个人费用,诺华的个人费用,在提交的工作之外。
Conflict of interest: Dr. Oqueka has nothing to disclose.
Conflict of interest: Dr. Frankenberger has nothing to disclose.
Conflict of interest: Dr. Kreuter reports grants and personal fees from Roche/InterMune, grants and personal fees from Boehringer Ingelheim, outside the submitted work.
- 收到November 26, 2019.
- AcceptedApril 7, 2020.
- 复制right ©ERS 2020